From: Focal segmental glomerulosclerosis: molecular genetics and targeted therapies
Primary (idiopathic) FSGS |
Secondary FSGS |
1. Genetic mutations |
  NPHS1 |
  NPHS2 |
  CD2AP |
  TRPC6 |
  ACTN4 |
  INF2 |
  ANLN |
  ARHGAP24 |
  ARHGDIA |
  WT-1 |
  LMX1B |
  LAMB2 |
  PAX2 |
  COQ2, COQ6, PDSS2, ADCK4 |
2. Virus associated |
 HIV |
 Parvovirus B19 |
3. Medication |
 Heroin |
 Interferon-α |
 Lithium |
 Pamidronate/alendronate |
 Anabolic steroids |
4. Adaptive structural-functional responses e.g., glomerular hypertrophy or hyperfiltration |
4.1 Reduced kidney mass |
 Oligomeganephronia |
 Unilateral kidney agenesis |
 Kidney dysplasia |
 Reflux nephropathy |
 Surgical kidney ablation |
 Chronic allograft nephropathy |
 Any advanced kidney disease with reduction in functioning nephrons |
4.2 Initially normal kidney mass |
 Diabetes mellitus |
 Hypertension |
 Obesity |
 Cyanotic congenital heart disease |
 Sickle cell anemia |
5. Malignancy (lymphoma) |
6. Nonspecific pattern of FSGS caused by kidney scarring |
Focal proliferative glomerulonephritis (IgA nephropathy, lupus nephritis, pauci-immune focal necrotizing and crescentic glomerulonephritis) |
Hereditary nephritis (Alport syndrome) |
Membranous glomerulopathy |
Thrombotic microangiopathy |